DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2005/0256029 A1 Murphy Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2005/0256029 A1 Murphy Et Al US 2005O256029A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0256029 A1 Murphy et al. (43) Pub. Date: Nov. 17, 2005 (54) METHODS AND COMPOSITIONS FOR Publication Classification ALLEVIATING STUTTERING (51) Int. Cl." ....................... A61K 38/17; A61K 31/573; (75) Inventors: John J. Murphy, Manhattan Beach, A61K 31/5513; A61K 31/473; CA (US); Kay Jorgenson D’Orlando, A61K 31/4745; A61K 31/515 Wayland, MA (US) (52) U.S. Cl. .............................. 514/2; 514/179; 514/270; 514/221; 514/300; 514/290 Correspondence Address: KATTEN MUCHIN ROSENMAN LLP (57) ABSTRACT 525 WEST MONROE STREET Methods of treating Stuttering include treating people with CHICAGO, IL 60661-3693 (US) gamma-aminobutyric acid (GABA) receptor modulators, including cyclopyrrolones. A Second active agent may be (73) Assignee: Indevus Pharmaceuticals, Inc., Lexing used with GABA receptor modulators. Active enantiomers, ton, MA active metabolites, and pharmaceutically acceptable Salts of gamma-aminobutyric acid receptor modulators, including (21) Appl. No.: 11/046,706 cyclopyrrolones, are acceptable components of the compo Filed: Feb. 1, 2005 Sitions. The cyclopyrrolone class of modulators includes (22) pagoclone, Suriclone, Zopiclone, 2-(7-chloro-2-naphthyri Related U.S. Application Data din-1,8-yl)-3-(5-methyl-2-oxohexyl)isoindolin-1-one, 2-(7- chloro-2-naphthyridin-18-yl)isoindolin-1-yl-4-acetami (63) Continuation of application No. 09/628,803, filed on dobutyrate, and 2-(7-chloro-1,8-naphthyridin-2yl)-3-(5- Jul. 28, 2000, now Pat. No. 6,855,721. methyl-5-hydroxy-2-oxohexyl)-1-isoindolinone. US 2005/0256029 A1 Nov. 17, 2005 METHODS AND COMPOSITIONS FOR 0006 Notably Wells, P. G. et al. Br J Psychiatry 1971, ALLEVIATING STUTTERING 119, 603, reported a placebo-controlled, double-blind study. Wells et al., randomized patients into treatment groups, 1. FIELD OF THE INVENTION included objective measures of Speech, and found a signifi cant improvement over an eight-week course. Objective 0001. The present invention relates generally to methods criteria in Such studies include the length of time to read a for treating Stuttering. The invention also relates to pharma Standard passage, the number of Syllabic repetitions in the ceutical compositions for treating Stuttering, comprising process of conveying Specific information, the time to gamma-aminobutyric acid modulators and pharmaceutically explain a Solution to a puzzle, and the like. Subsequent acceptable Salts thereof, including the cyclopyrrolones, Studies Support a significant improvement in the accessory notably pagoclone (+)2-(7-chloro-1,8-naphthyridine-2-yl)- Symptoms of Stuttering, including rapid blinking and jerking 3-(5-methyl-2-oxo-hexyl)-1-isoindolinone, alone or in movements of the upper body, but patient compliance is low combination with one or more pharmaceutically active because of Side-effects including dizzineSS and dysphoric agents, and a pharmaceutically acceptable carrier. "medicine-head’ symptoms. More Significant and disturbing are the long-term detrimental effects haloperidol and other 2. BACKGROUND OF THE INVENTION neuroleptics have on Voluntary muscle function, known as 0002 2.1. Developmental and Neurogenic Stuttering. tardive dyskinesia. 0.003 Stuttering is a poorly understood condition marked 0007 2.2 The GABA Neuronal Pathway. by frequent repetitions or prolongations of Sounds, and an 0008 One of the main neurotransmitters involved in impaired fluency of Speech. Accessory features of Stuttering, inhibitory neuronal pathways is gamma-aminobutyric acid possibly resulting from the attempts of the Stutterer to or GABA. GABA appears to function mainly at two types of control the Stuttering, include blocks in the flow of Speech receptors, termed GABA and GABA receptors, that have Sounds, Swallowing, grimacing, tremors of the jaw and different structures. The GABAA receptor is a GABA-gated tongue, coughing, rapid eye blinking, and jerking move chloride ion channel and the GABA receptor is a G-protein ments of the arm or upper trunk. (Brady, J. Am J Psychiatry, coupled regulator of potassium conductance. GABA recep 1991, 148, 1309). One form, developmental stuttering, often tors can be modulated by Several classes of pharmacologic appears in early human childhood or adolescence, and agents, notably the benzodiazepines, the barbiturates, con affects predominantly males. An estimated three million Vulsants, and neurosteroids of the class epiallopregnanolone Americans are affected and the condition is not dependent on or epalons. These classes of agents appear to act at different, language type or cultural background. A leSS frequent type discrete sites on the GABAA receptor. Thus, the diversity of is neurogenic Stuttering, often a result of head trauma or effects expressed by these agents ranges from the tranquil Stroke. Subtle differences between neurogenic and develop izing effects of benzodiazepines, and the Sedative effects of mental dysfluency may be observed, for example in the barbiturates to the convulsant effects of t-butyl-bicyclophos repetitive reading test, where Sufferers of developmental phorothionate (TBPS), which may act on GABAA receptors Stuttering often improve by the tenth reading of a passage, asSociated with clathrin-coated vesicles. The cyclopyrrolo but Sufferers of neurogenic Stuttering do not. A third type is nes have demonstrated high affinity for the benzodiazepine drug-induced Stuttering, an increasingly frequent problem. binding site on the GABAA receptor. Some cyclopyrrolones, 0004. In the past, stutterers have been treated by a wide e.g., pagoclone, have a pharmacological profile consistent variety of methods devised by some of the best minds of the with that of a partial agonist at this site. Partial agonists can time. Both Hippocrates and Hieronymus Merculialis recom be efficacious in producing Some effects, e.g., anxiolysis, in mended oral or head Surgeries or mutilations. In this century, common with full agonists, but may be less effective in psychiatric treatments have been tried ranging from operant producing others, e.g., Sedation. Antagonists, or “blockers,” reinforcement to psychotherapy for presumed unconscious on the other hand, counteract the action of endogenous conflicts. However, those who stutter are remarkably well GABA and exogenous agonists. Inverse agonists decrease adjusted, and are Similar to those who do not Stutter in the inherent or constitutive. Stimulation by a receptor in the personality traits. Current methods include Speech training absence of an agonist. Modulator is a term that includes and pharmaceutical intervention. The improvement for agonist, partial agonist, inverse agonist, antagonist, neu patients, unfortunately, has been limited. rotransmitter, reuptake inhibitor, and degradation inhibitor. Antagonists are often relatively Specific to a particular class 0005 The spectrum of experimental pharmaceutical of agonists. For example, flumazenil, a benzodiazepine interventions has been broad. At times, carbon dioxide inhalation, Stimulants (notably methamphetamine), Seda antagonist, blocks the function of benzodiazepines including tives (in particular, phenobarbital combined with belladonna flunitrazepam, diazepam, pinazepam, prazepam, halazepam, and ergotamine), an early antihistamine (hydroxy Zinc), bro camazepam, and flurazepam. mides, thiamine Supplements, an antihypertensive (reser 0009 GABAA receptor modulators, especially agonists pine), the tranquilizer meprobamate, anxiolytics (in particu and partial agonists, are also known to act as antiphobics, lar, benzodiazepines), neuroleptics (including thioridazine, myorelaxants, anti-epileptics, and by other means. GABAA chlorpromazine and trifluoperazine), Verapamil, beta-adren receptor modulators act as myorelaxants by decreasing ergic blockers (including propranolol, betaxolol, and Oxpre muscle Stiffness, decreasing tonus, and reducing Voluntary nolol), an anticonvulsant (carbamazepine), and cholinergic muscle contraction in Spasticity. Also Some GABA modu agents (neostigmine and bethanecol) have been tried for lators have hypnotic, Sleep-inducing, amnestic, Sedative, Stuttering, but all with unsustainable Success. Haloperidol and/or anti-convulsant effects. Antagonists of GABAA has been particularly well Studied as an agent for the receptor function tend to block these effects and may even attenuation of Stuttering. be anxiogenic or proconvulsant in Some individuals. US 2005/0256029 A1 Nov. 17, 2005 0.010 Many of the GABA agonists, in particular the methyl-1-piperazinecarboxylic acid 6-(5-chloro-2-pyridi benzodiazepines and the cyclopyrrolones, act to reduce nyl)-6,7-dihydro-7-oxo-5H-pyrrolo-3.4pyrazin-5-yl ester), anxiety and induce a Sense of calm. In consequence, these and the compound of U.S. Pat. No. 5,676,831. Use of active agents are termed anxiolytics. It has long been thought that metabolites, active enantiomers, active racemic mixtures, or anxiety is a component of Stuttering, although the cellular pharmaceutically acceptable Salts of cyclopyrrolones, as an bases for anxiety and Stuttering are not at all clear. In anti-Stuttering medication is contemplated. contrast, however, the results of placebo-controlled Studies 0018. In a yet further object of the invention, pagoclone, of benzodiazepines on Stuttering have been inconsistent and its active metabolite, its active enantiomer, an active racemic disappointing (Brady, Supra). mixture comprising pagoclone, or pharmaceutically accept 0.011) 2.3 Drug-Induced Stuttering.
Load more

Recommended publications
  • Preliminary Effects of Pagoclone, a Partial GABA Agonist, On
    ORIGINAL RESEARCH Preliminary effects of pagoclone, a partial GABAA agonist, on neuropsychological performance 1 Angela F Caveney Abstract: Pagoclone is a novel cyclopyrrolone that acts as a partial GABAA receptor agonist. Bruno Giordani1 Preclinical studies suggest that pagoclone may have clinical utility as an anxiolytic agent, as George M Haig2 well as a reduced incidence of side-effects. The present study was conducted to determine whether pagoclone would affect healthy individuals’ performances on neuropsychological 1Department of Psychiatry, University of Michigan, Ann Arbor, MI, USA; measures as a function of dose within the projected therapeutic range. Twelve healthy adult 2Neurosciences Development, Abbott subjects were randomly assigned to dosage groups in a 3-way crossover study. Participants Laboratories, Abbott Park, IL, USA were administered neuropsychological measures six hours following dosing on Day 1 and Day 6 of administration of the drug. Dose effects were noted on measures of alertness, learning, and memory and movement time. Signifi cant effects were also noted on measures of alertness, learning and memory, information processing and psychomotor speed. Overall, the results of this small, preliminary study do not support a fi nding of behavioral toxicity for these doses of pagoclone. Rather, a pattern was found of transient and mild negative effects on learning and memory scores at the highest dose administered, though these changes were small and no longer evident by the sixth day of use. Keywords: pagoclone, cyclopyrrolone, neuropsychological, memory, generalized anxiety disorder Introduction Behavioral toxicity refers to the extent to which a drug affects an individual’s ability to perform the psychomotor and cognitive tasks of everyday life (Ramaekers 1998).
    [Show full text]
  • Drug Class Review Newer Drugs for Insomnia
    Drug Class Review Newer Drugs for Insomnia Final Update 2 Report October 2008 The Agency for Healthcare Research and Quality has not yet seen or approved this report. The purpose of Drug Effectiveness Review Project reports is to make available information regarding the comparative clinical effectiveness and harms of different drugs. Reports are not usage guidelines, nor should they be read as an endorsement of or recommendation for any particular drug, use, or approach. Oregon Health & Science University does not recommend or endorse any guideline or recommendation developed by users of these reports. Update 1: July 2006 Original: December 2005 Susan Carson, MPH Marian S. McDonagh, PharmD Sujata Thakurta, MPA:HA Po-Yin Yen, MS Drug Effectiveness Review Project Marian McDonagh, PharmD, Principal Investigator Oregon Evidence-based Practice Center Mark Helfand, MD, MPH, Director Copyright © 2008 by Oregon Health & Science University Portland, Oregon 97239. All rights reserved. Final Report Update 2 Drug Effectiveness Review Project The medical literature relating to the topic is scanned periodically (see http://www.ohsu.edu/xd/research/centers-institutes/evidence-based-policy- center/derp/documents/methods.cfm for scanning process description). Upon review of the last scan, the Drug Effectiveness Review Project governance group elected not to proceed with another full update of this report based on the information contained in the scan. Some portions of the report may not be up to date. Prior versions of this report can be accessed at the DERP website. Insomnia Page 2 of 87 Final Report Update 2 Drug Effectiveness Review Project TABLE OF CONTENTS INTRODUCTION ............................................................................................................. 6 Scope and Key Questions ......................................................................................................................
    [Show full text]
  • GABA Receptors
    D Reviews • BIOTREND Reviews • BIOTREND Reviews • BIOTREND Reviews • BIOTREND Reviews Review No.7 / 1-2011 GABA receptors Wolfgang Froestl , CNS & Chemistry Expert, AC Immune SA, PSE Building B - EPFL, CH-1015 Lausanne, Phone: +41 21 693 91 43, FAX: +41 21 693 91 20, E-mail: [email protected] GABA Activation of the GABA A receptor leads to an influx of chloride GABA ( -aminobutyric acid; Figure 1) is the most important and ions and to a hyperpolarization of the membrane. 16 subunits with γ most abundant inhibitory neurotransmitter in the mammalian molecular weights between 50 and 65 kD have been identified brain 1,2 , where it was first discovered in 1950 3-5 . It is a small achiral so far, 6 subunits, 3 subunits, 3 subunits, and the , , α β γ δ ε θ molecule with molecular weight of 103 g/mol and high water solu - and subunits 8,9 . π bility. At 25°C one gram of water can dissolve 1.3 grams of GABA. 2 Such a hydrophilic molecule (log P = -2.13, PSA = 63.3 Å ) cannot In the meantime all GABA A receptor binding sites have been eluci - cross the blood brain barrier. It is produced in the brain by decarb- dated in great detail. The GABA site is located at the interface oxylation of L-glutamic acid by the enzyme glutamic acid decarb- between and subunits. Benzodiazepines interact with subunit α β oxylase (GAD, EC 4.1.1.15). It is a neutral amino acid with pK = combinations ( ) ( ) , which is the most abundant combi - 1 α1 2 β2 2 γ2 4.23 and pK = 10.43.
    [Show full text]
  • WO 2015/072852 Al 21 May 2015 (21.05.2015) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/072852 Al 21 May 2015 (21.05.2015) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 36/84 (2006.01) A61K 31/5513 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/045 (2006.01) A61P 31/22 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/522 (2006.01) A61K 45/06 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, PCT/NL20 14/050780 KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (22) International Filing Date: MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, 13 November 2014 (13.1 1.2014) PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (25) Filing Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 61/903,430 13 November 2013 (13. 11.2013) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (71) Applicant: RJG DEVELOPMENTS B.V.
    [Show full text]
  • CNS Drug Reviews Vol
    CNS Drug Reviews Vol. 10, No. 1, pp. 45–76 © 2004 Neva Press, Branford, Connecticut Clinical Pharmacology, Clinical Efficacy, and Behavioral Toxicity of Alprazolam: A Review of the Literature Joris C. Verster and Edmund R. Volkerts Utrecht Institute for Pharmaceutical Sciences, Department of Psychopharmacology, University of Utrecht, Utrecht, The Netherlands Keywords: Alprazolam — Benzodiazepines — Anxiety — Depression — Panic — Sedation. ABSTRACT Alprazolam is a benzodiazepine derivative that is currently used in the treatment of generalized anxiety, panic attacks with or without agoraphobia, and depression. Alprazo- lam has a fast onset of symptom relief (within the first week); it is unlikely to produce de- pendency or abuse. No tolerance to its therapeutic effect has been reported. At discontinu- ation of alprazolam treatment, withdrawal and rebound symptoms are common. Hence, alprazolam discontinuation must be tapered. An exhaustive review of the literature showed that alprazolam is significantly superior to placebo, and is at least equally effective in the relief of symptoms as tricyclic antide- pressants (TCAs), such as imipramine. However, although alprazolam and imipramine are significantly more effective than placebo in the treatment of panic attacks, Selective Sero- tonin Reuptake Inhibitors (SSRIs) appear to be superior to either of the two drugs. Therefore, alprazolam is recommended as a second line treatment option, when SSRIs are not effective or well tolerated. In addition to its therapeutic effects, alprazolam produces adverse effects, such as drowsiness and sedation. Since alprazolam is widely used, many clinical studies investi- gated its cognitive and psychomotor effects. It is evident from these studies that alprazo- lam may impair performance in a variety of skills in healthy volunteers as well as in pa- tients.
    [Show full text]
  • In the Treatment of Generalised Anxiety Disorder Does Pharmacology
    Characteristics Table for The Clinical Question: In the treatment of generalised anxiety disorder does 6/18/2010 12:21:10 pharmacology improve outcome? Comparisons Included in this Clinical Question Anticonvulsants versus Placebo Anticonvulsants vs Venlafaxine (SNRI) Antihistamine vs Placebo Benzodiazepines versus vs Placebo Anticonvulsants FELTNER2003 DARCIS1995 KASPER2009 KASPER2009 LADER1998 FELTNER2003 MONTGOMERY2006 MONTGOMERY2006 LLORCA2002 PANDE2003 MONTGOMERY2008 PFIZER2005 PANDE2003 RICKELS2005 PFIZER2005 POHL2005 RICKELS2005 Benzodiazepines versus Azapirones Benzodiazepines versus Placebo Buspirone vs Placebo Duloxetine (SNRI) vs. placebo BOURIN1992 ANDREATINI2002 DAVIDSON1999 HARTFORD2007 ANSSEAU2001 LADER1998 KOPONEN2007 CUTLER1993A MAJERCSIK2003 NICOLINI2009 FELTNER2003 POLLACK1997 RYNN2008 FRESQUET2000 SRAMEK1996 HACKETT2003 LYDIARD1997 MCLEOD1992 MOLLER2001 PANDE2003 PFIZER2008 RICKELS2000B RICKELS2005 Duloxetine (SNRI) vs. Venlafaxine Quetiapine versus Placebo SSRI vs Venlafaxine SSRIs versus Placebo (SNRI) ASTRAZENECA2007A BOSE2008 ALLGULANDER2004 HARTFORD2007 ASTRAZENECA2007B ASTRAZENECA2007A NICOLINI2009 ASTRAZENECA2007C ASTRAZENECA2007B ASTRAZENECA2008 BALDWIN2006 BOSE2008 BRAWMAN-MINTZER2006 DAVIDSON2004 GOODMAN2005 GSK2002 GSK2005 HEWETT2001 LENZE2005 LENZE2009 PFIZER2008 POLLACK2001 RICKELS2003 SSRIs versus SSRIs TCA vs Placebo Venlafaxine (SNRI) versus Azapirones Venlafaxine (SNRI) versus placebo BALDWIN2006 MCLEOD1992 DAVIDSON1999 ALLGULANDER2001 BALL2005 BOSE2008 BIELSKI2005 DAVIDSON1999 GELENBERG2000 HACKETT2003
    [Show full text]
  • Drug Class Review on Newer Sedative Hypnotics
    Drug Class Review on Newer Sedative Hypnotics Final Report December 2005 The Agency for Healthcare Research and Quality has not yet seen or approved this report The purpose of this report is to make available information regarding the comparative effectiveness and safety profiles of different drugs within pharmaceutical classes. Reports are not usage guidelines, nor should they be read as an endorsement of, or recommendation for, any particular drug, use or approach. Oregon Health & Science University does not recommend or endorse any guideline or recommendation developed by users of these reports. Susan Carson, MPH Po-Yin Yen, MS Marian S. McDonagh, PharmD Oregon Evidence-based Practice Center Oregon Health & Science University Mark Helfand, MD, MPH, Director Copyright © 2005 by Oregon Health & Science University Portland, Oregon 97201. All rights reserved. Final Report Drug Effectiveness Review Project TABLE OF CONTENTS Introduction....................................................................................................................... 4 Scope and Key Questions ............................................................................................. 4 Methods.............................................................................................................................. 6 Literature Search........................................................................................................... 6 Study Selection ............................................................................................................
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • (Mmnm) and Auditory Evoked Field Component N100m
    Neuropsychopharmacology (2004) 29, 1723–1733 & 2004 Nature Publishing Group All rights reserved 0893-133X/04 $30.00 www.neuropsychopharmacology.org Effects of Lorazepam on the Neuromagnetic Mismatch Negativity (MMNm) and Auditory Evoked Field Component N100m Timm Rosburg*,1,2,3, Varvara Marinou1, Jens Haueisen2, Stefan Smesny1 and Heinrich Sauer1 1 2 Department of Psychiatry, Friedrich-Schiller-University Jena, Jena, Germany; Biomagnetic Center, Department of Neurology, Friedrich-Schiller- University Jena, Jena, Germany; 3Department of Epileptology, University of Bonn, Bonn, Germany The mismatch negativity (MMN) as an auditory evoked potential is thought to reflect an early, preconscious attention process. While this component has gained great importance in studies on clinical populations and in basic research on auditory information processing, the involvement of different neurotransmitters in the generation of this component is less well understood. We investigated the impact of the benzodiazepine lorazepam as a GABA agonist on the neuromagnetic MMN (MMNm) and auditory evoked field component N100m. A group of 12 healthy subjects was studied in single blind trials under the following three conditions: after the intake of 1.25 mg lorazepam, 100 mg caffeine or placebo. Neuromagnetic recordings were obtained before drug intake and three times after it. Controlled visual attention was tested additionally using a version of the Continuous Performance Test (CPT). The neuromagnetic activity was reconstructed by a single moving dipole, and the dipole moment and its latency were compared between conditions and time points of measurement. Lorazepam diminished the signal detection performance in the CPT 25 min after drug intake. The source of the field component N100m was attenuated, most significantly in the recording 105 min after lorazepam intake.
    [Show full text]
  • Pharmacological Aspects
    Pharmacological aspects Psychopharmacology of anxiety disorders Giovanni B. Cassano, MD; Nicolò Baldini Rossi, MD; Stefano Pini, MD A nxiety disorders are the most common and among the most disabling of mental disorders in adults and adolescents.1 Although many are highly circum- scribed fears of mild-to-moderate severity, it has been estimated by the Epidemiological Catchment Area (ECA) study2 that approximately one quarter of people will experience severe symptoms, disability, and handicap as a consequence of anxiety disorders at some time dur- ing their lifetime.These disorders are associated with sig- nificant morbidity3 and increased mortality, probably as a consequence of increased suicide rates among suffer- Exposure of the general population to a 1:4 lifetime risk of ers.The direct and indirect costs to the health service and disabling anxiety has inspired generations of fundamental economy are considerable.Although persons who suffer and clinical psychopharmacologists, from the era of the from anxiety disorders are high consumers of all types of earliest benzodiazepines (BZ) to that of the selective sero- health services, only a minority receive specific help.4 tonin reuptake inhibitors (SSRIs) and related compounds, The spectrum of anxiety disorders includes generalized eg, the serotonin and norepinephrine reuptake inhibitors anxiety disorder (GAD), panic disorder (PD) and ago- (SNRIs). This comprehensive practical review summarizes raphobia, obsessive-compulsive disorder (OCD), phobic current therapeutic research across the spectrum of indi- disorder (including social phobia), and posttraumatic vidual disorders: generalized anxiety disorder (GAD), panic stress disorder (PTSD). With the discovery of new psy- disorder (PD) and agoraphobia (social anxiety disorder), chotropic medications, specific diagnosis within this spec- compulsive disorder (OCD), phobic disorder (including trum is essential because each of these disorders social phobia), and posttraumatic stress disorder (PTSD).
    [Show full text]
  • Validated Stability Indicating HPLC Method for Determination of Zolpidem in the Presence of Its Degradation Products
    The Open Conference Proceedings Journal, 2012, 3, 13-17 13 Open Access Validated Stability Indicating HPLC Method for Determination of Zolpidem in the Presence of Its Degradation Products Effat Souri*, Azadeh Shirvin, Nazanin Shabani Ravari, Farhad Alvandifar and Maliheh Barazandeh Tehrani Department of Medicinal Chemistry, Faculty of Pharmacy and Drug Design and Development Research Center, Tehran University of Medical Sciences, Tehran (14155-6451), Iran Abstract: Zolpidem is a hypnotic agent used for the treatment of insomnia. In this study a stability indicating HPLC method was developed for the determination of zolpidem in the presence of its degradation products. Stress degradation of zolpidem was performed under acidic, alkaline, oxidative, heat and photolytic conditions. Separation of zolpidem and its degradation products were performed on a Nova-Pak CN column using KH2PO4 30 mM and acetonitrile (65: 35, v/v at pH 6) as mobile phase. Acceptable linearity (r2 >0.999) and precision (CV value <1.5%) were achieved over the concen- tration range of 1-20 g/mL. Degradation of zolpidem was observed under acidic, alkaline, oxidative conditions and also exposure to UV light. The proposed method was used for assay determination of zolpidem tablets with no interfering from excipients. Keywords: Zolpidem, HPLC, Stability indicating, Degradation. INTRODUCTION guidelines to be used for determination of zolpidem in the presence of its degradation products. Zolpidem, 2- (4-methylphenyl)-N, N, 6- trimethyl- imidiazo [1, 2-a] pyridine-3- acetamide (Fig. 1), is a non- benzodiazepine hypnotic agent related to imidazopyridine MATERIALS AND METHODS class. Zolpidem is currently formulated as a hemitartrate salt Materials in tablets.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2019 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]